UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Leukemia, 2023-11, Vol.37 (11), p.2309-2313

2023

Link zum Volltext

Verfügbarkeit prüfen

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

Bone marrow transplantation (Basingstoke), 2024-02, Vol.59 (2), p.224-231

2024

Link zum Volltext

Verfügbarkeit prüfen

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient

Leukemia, 2017-07, Vol.31 (7), p.1637-1640

2017

Link zum Volltext

Verfügbarkeit prüfen

P725: METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES

HemaSphere, 2022-06, Vol.6, p.620-621

2022

Link zum Volltext

Verfügbarkeit prüfen

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

Leukemia, 2016-02, Vol.30 (2), p.261-267

2016

Link zum Volltext

Verfügbarkeit prüfen

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

Leukemia, 2017-10, Vol.31 (10), p.2247-2251

2017

Link zum Volltext

Verfügbarkeit prüfen

Implementation of Diagnostic Flow Cytometry Allows for the Dissection of Age Related Loss of Y Chromosome from Myelodysplastic Syndrome (MDS)

Leukemia research, 2017-04, Vol.55, p.S98-S98

2017

Link zum Volltext

Verfügbarkeit prüfen

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

Leukemia, 2016-02, Vol.30 (2), p.517-520

2016

Link zum Volltext

Verfügbarkeit prüfen

P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS

HemaSphere, 2022-06, Vol.6, p.647-648

2022

Link zum Volltext

Verfügbarkeit prüfen

P747: LR‐MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME‐RELATED GENES IN SPECIFIC CELL POPULATIONS

HemaSphere, 2022-06, Vol.6, p.642-643

2022

Link zum Volltext

Verfügbarkeit prüfen

107 MONITORING OF THERAPEUTIC RESPONSE TO LENALIDOMIDE IN DEL(5Q) MDS USING A RAPID 5-PARAMETER FLOW CYTOMETRIC DEL(5Q)-SCORE

Leukemia research, 2015-04, Vol.39, p.S55-S55

2015

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS01-Diagnosis/AS01b-Flow cytometry: FLOW CYTOMETRIC SCREENING IN PERIPHERAL BLOOD TO GUIDE THE DIAGNOSTIC ALGORITHM IN MDS

Leukemia research, 2023-05, Vol.128, p.107140, Article 107140

2023

Link zum Volltext

Verfügbarkeit prüfen

P-057 Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile

Leukemia research, 2013-05, Vol.37, p.S47-S48

2013

Link zum Volltext

Verfügbarkeit prüfen

P-059 Distribution of clonal cells in flow cytometry-defined subpopulations of patients with myelodysplastic syndromes (MDS)

Leukemia research, 2013-05, Vol.37, p.S48-S49

2013

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment

Leukemia research, 2021-09, Vol.108, p.106681, Article 106681.43

2021

Link zum Volltext

Verfügbarkeit prüfen

P44 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL BLAST COUNT IN MYELODYSPLASTIC SYNDROMES

Leukemia research, 2021-09, Vol.108

2021

Link zum Volltext

Verfügbarkeit prüfen

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation

Blood cancer journal (New York), 2013-08, Vol.3 (8), p.e136-e136

2013

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

Leukemia research, 2023-05, Vol.128, p.107225, Article 107225

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

Bone marrow transplantation (Basingstoke), 2022-06, Vol.57 (6), p.896-902

2022

Link zum Volltext

Verfügbarkeit prüfen

Timing of allo-HCT in CMML

Blood, 2022-09, Vol.140 (12), p.1452-1452

2022

Link zum Volltext

Verfügbarkeit prüfen

P46 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: MOVING CLOSER TOWARDS EXPLAINABLE AI APPLICATIONS: DEVELOPMENT OF A SEMANTIC AND CAUSAL MODEL FOR PERSONALIZED TREATMENT DECISION MAKING IN MYELODYSPLASTIC SYNDROMES

Leukemia research, 2021-09, Vol.108

2021

Link zum Volltext

Verfügbarkeit prüfen

Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment

Leukemia research, 2021-09, Vol.108, p.106681, Article 106681.45

2021

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Haematologica (Roma), 2012-09, Vol.97 (9), p.e34-e35

2012

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Haematologica (Roma), 2011-10, Vol.96 (10), p.1568-1570

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(17)
Hematology
(15)
Humans
(13)
Oncology
(11)
Materials Science
(10)
Technology
(10)
Materials Science, Multidisciplinary
(9)
Male
(8)
Metallurgy & Metallurgical Engineering
(8)
Female
(7)
Exact Sciences And Technology
(6)
Middle Aged
(6)
Acute Myeloid Leukemia
(5)
Aged
(5)
Applied Sciences
(5)
Leukemia
(5)
Metals. Metallurgy
(5)
Myelodysplastic Syndromes - Drug Therapy
(5)
Patients
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient

P725: METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

Implementation of Diagnostic Flow Cytometry Allows for the Dissection of Age Related Loss of Y Chromosome from Myelodysplastic Syndrome (MDS)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden

P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS

P747: LR‐MDS IS CHARACTERIZED BY DIFFERENTIAL EXPRESSION OF INFLAMMASOME‐RELATED GENES IN SPECIFIC CELL POPULATIONS

107 MONITORING OF THERAPEUTIC RESPONSE TO LENALIDOMIDE IN DEL(5Q) MDS USING A RAPID 5-PARAMETER FLOW CYTOMETRIC DEL(5Q)-SCORE

S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER‐RISK MYELODYSPLASTIC SYNDROMES

Topic: AS01-Diagnosis/AS01b-Flow cytometry: FLOW CYTOMETRIC SCREENING IN PERIPHERAL BLOOD TO GUIDE THE DIAGNOSTIC ALGORITHM IN MDS

P-057 Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile

P-059 Distribution of clonal cells in flow cytometry-defined subpopulations of patients with myelodysplastic syndromes (MDS)

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment

P44 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: PROGNOSTIC SIGNIFICANCE OF HISTOLOGICAL BLAST COUNT IN MYELODYSPLASTIC SYNDROMES

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation

Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

Timing of allo-HCT in CMML

P46 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: MOVING CLOSER TOWARDS EXPLAINABLE AI APPLICATIONS: DEVELOPMENT OF A SEMANTIC AND CAUSAL MODEL FOR PERSONALIZED TREATMENT DECISION MAKING IN MYELODYSPLASTIC SYNDROMES

Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Suchergebnisse filtern